Regulations and Compliance
At Blue Latitude Health, a large part of our work hinges on our ability to operate effectively within strict regulatory environments and adhere to compliance requirements.
This is where you’ll find our commentary, articles, and resources around how we work within those complex regulatory environments while achieving the best outcomes for our clients.
Perspective on biotech leaders
|27th November 2017
Seven industry trailblazers reveal the trends, challenges and opportunities they anticipate in the biotech sector, from empowering patients to deciphering big data.
21st Century Cures Act: a commercial perspective on how the new FDA regulation could revolutionise use of RWE and analytics in healthcare
|15th June 2017
The 21st Century Cures Act was signed into law last December during the Obama administration. It brings numerous changes to the US drug development landscape, impacting patients, academia, research institutions, and industry. Over the last number of months Blue Latitude have been engaging with US pharma companies to help our clients understand its implications and how it could be leveraged.
How to design patient services with social media within the ABPI code guidelines
|20th May 2015
In this blog, Senior Consultant Craig Moore, from the Blue Latitude Health Strategy team, discusses the application of the ABPI Code, including incorporating social media into digital patient services.
Not all data is created equal
|19th March 2015
Following on from our Top 7 Trends in Pharma Marketing for 2015 post, it is clear that the pharma marketing trends we expect to transform the healthcare sector are easier said than done.
Aurélie Pols from Mind Your Privacy has written this guest blog to talk about the first steps you need to take when considering data privacy and security.
Is the future of pharma marketing in our DNA?
|17th February 2014
Customer data is collected and used by almost every marketing department globally to better target audiences, so is it now time to take the next step, and add DNA to the pharma marketing mix? Mark Assenti explores the ethical and scientific issues behind genetic marketing.